HK Innoen Signs Contract for Outsourced Production of Cell Lines for Exosome Therapy Development

Brexogen and Contract Manufacturing Agreement

HK Innoen is promoting the contract manufacturing of cell lines for the development of exosome therapeutics derived from stem cells.

HK Innoen (left) and Brexogen CI. [Image provided by HK Innoen]

On the 20th, HK Innoen announced that it signed a contract manufacturing agreement for cell lines used in exosome therapeutic development with Brexogen, a company specializing in exosome therapeutics. Through this agreement, HK Innoen will produce Brexogen's cell lines for exosome therapeutic development. Production will take place at HK Innoen's Cell and Gene Therapy Center established in Hanam, Gyeonggi Province.

Exosomes are nano-sized particles secreted by cells, and pharmaceutical and biotech companies both domestically and internationally are developing exosomes as biomarkers, drug delivery systems (DDS), or therapeutic agents.

In the case of existing stem cell-derived exosome therapeutics, the state of exosomes generated within cells varies, making it difficult to obtain high-purity exosomes and to produce them in large quantities. Brexogen is developing various exosome therapeutics that overcome these limitations. Brexogen’s exosome platform, 'BG-Platform,' applies technology that maximizes the efficacy of stem cells producing exosomes while controlling the active components within the exosomes. This platform has scalability that allows the development of exosome therapeutics with various mechanisms of action targeting multiple diseases.

HK Innoen established a Cell and Gene Therapy Center in Hanam, Gyeonggi Province in 2020 and obtained a license for manufacturing advanced biopharmaceuticals last year. At this center, HK Innoen conducts research on CAR-T and CAR-NK cell gene therapies, as well as joint research or contract manufacturing (CMO) and contract development and manufacturing (CDMO) with domestic companies such as GC Cell, GI Cell, Cellinsels, and Ainv.

Won Sung-yong, Director (Executive Director) of HK Innoen’s Bio Research Institute, said, "Based on excellent Good Manufacturing Practice (GMP)-based technology and know-how, we will do our utmost to ensure the successful development of exosome therapeutics using Brexogen’s core technology." Kim Soo, CEO of Brexogen, said, "Through collaboration with HK Innoen’s Cell and Gene Therapy Center, we will diversify Brexogen’s exosome therapeutic development and do our best to rapidly lead the global exosome market."

This content was produced with the assistance of AI translation services.